Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 3, 2013, Pages 458-459

  Herman, Joseph M ^a   Fan, Katherine Y ^a   Wild, Aaron T ^a   Wood, Laura D ^b   Blackford, Amanda L ^a   Donehower, Ross C ^a   Hidalgo, Manuel ^c   Schulick, Richard D ^d   Edil, Barish H ^d   Choti, Michael A ^a   Hruban, Ralph H ^c   Pawlik, Timothy M ^a   Cameron, John L ^a   Laheru, Daniel A ^a   Iacobuzio Donahue, Christine A ^c   Wolfgang, Christopher L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADJUVANT CHEMORADIOTHERAPY; APOPTOSIS; AUTOPSY; CANCER ADJUVANT THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; GENE DELETION; GENE MUTATION; HUMAN; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

EID: 84884827171     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.06.2039     Document Type: Article

References (4)

1. A. Blackford, O.K. Serrano, and C.L. Wolfgang SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer Clin Cancer Res 15 2009 4674 4679
2. C.A. Iacobuzio-Donahue, B. Fu, and S. Yachida PC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
3. S.A. Hahn, M. Schutte, and A.T. Hoque DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 271 1996 350 353
4. C.H. Crane, G.R. Varadhachary, and J.S. Yordy Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression J Clin Oncol 29 2011 3037 3043